title: Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
abstract: BACKGROUND
  Distal-type chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease for which a new therapeutic strategy needs to be developed. We examined the effects of percutaneous transluminal pulmonary angioplasty (PTPA).
  
  
  RESULTS
  We prospectively enrolled 12 patients with distal-type CTEPH. After stabilizing their condition with pulmonary vasodilators, we then performed PTPA, which markedly improved pulmonary hemodynamics and pulmonary artery structure, as confirmed by angiography and optical coherence tomography, and also significantly improved their long-term prognosis compared with 39 historical controls.
  
  
  CONCLUSIONS
  PTPA is a promising therapeutic option for distal-type CTEPH.
authors.affiliation: Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Sugimura
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fukumoto
authors.forename: Kimio
authors.initials: K
authors.lastname: Satoh
authors.forename: Kotaro
authors.initials: K
authors.lastname: Nochioka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Miura
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Aoki
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Tatebe
authors.forename: Saori
authors.initials: S
authors.lastname: Miyamichi-Yamamoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimokawa
mesh_terms: D000368:Aged; D017130:Angioplasty / Q000379:methods*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077300:Bosentan; D002908:Chronic Disease; D003131:Combined Modality Therapy; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D011652:Pulmonary Circulation / Q000187:drug effects / Q000502:physiology*; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; C048081:beraprost; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D000077300:Bosentan